^
    2d
    VENETACIBLE: Plasma Dosage of Venetoclax in the Fup of AML Patients Treated With Aza + Ven (clinicaltrials.gov)
    P=N/A, N=20, Completed, Centre Hospitalier Universitaire de Nice | Active, not recruiting --> Completed | Trial completion date: Oct 2025 --> Mar 2025
    Trial completion • Trial completion date
    |
    Venclexta (venetoclax) • azacitidine
    2d
    Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm (clinicaltrials.gov)
    P2, N=132, Active, not recruiting, National Cancer Institute (NCI) | Suspended --> Active, not recruiting
    Enrollment closed
    |
    Venclexta (venetoclax) • Inqovi (decitabine/cedazuridine)
    2d
    NAMPT inhibition uncovers therapeutic vulnerabilities to venetoclax and chemotherapy in acute myelogenous leukemia. (PubMed, Leuk Lymphoma)
    Proteomic profiling showed that NAMPT inhibition with KPT-9274 induced adaptive upregulation of BCL2, an anti-apoptotic protein, highlighting a survival mechanism...Additionally, NAMPT inhibition reduced PARP activity and impaired DNA repair pathways, sensitizing AML cells to cytarabine and hypomethylating agents. Together, these results demonstrate that NAMPT inhibition both potentiates venetoclax activity and enhances the cytotoxic effects of standard chemotherapies by targeting metabolic and DNA repair vulnerabilities. These findings provide strong preclinical support for evaluating NAMPT and BCL2 dual inhibition strategies in future AML clinical trials.
    Journal • PARP Biomarker • IO biomarker
    |
    MCL1 (Myeloid cell leukemia 1) • BCL2L1 (BCL2-like 1) • NAMPT (Nicotinamide Phosphoribosyltransferase)
    |
    Venclexta (venetoclax) • cytarabine • padnarsertib (KPT-9274)
    3d
    A relapsed/refractory acute promyelocytic leukemia achieving complete response after chemotherapy with venetoclax. (PubMed, Medicine (Baltimore))
    For relapsed and refractory APL, relevant drug resistance gene monitoring should be carried out. Some relapsed and refractory APL patients who do not respond to conventional treatment are at risk of death. We report a successful case, the regimen of VEN targeted therapy combined with chemotherapy still holds promise for the treatment of future relapsed/refractory APL.
    Journal
    |
    DNMT3A (DNA methyltransferase 1)
    |
    Venclexta (venetoclax) • cytarabine • idarubicin hydrochloride
    3d
    MM1YA-A04: Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MyeloMATCH Treatment Trial) (clinicaltrials.gov)
    P2, N=162, Not yet recruiting, National Cancer Institute (NCI) | Trial completion date: Jul 2028 --> Nov 2027 | Initiation date: Nov 2025 --> Feb 2026 | Trial primary completion date: Jul 2028 --> Nov 2027
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    Venclexta (venetoclax) • cytarabine • Mylotarg (gemtuzumab ozogamicin) • daunorubicin • Starasid (cytarabine ocfosfate)
    3d
    FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=33, Not yet recruiting, Montefiore Medical Center
    New P1 trial
    |
    Venclexta (venetoclax) • decitabine • camibirstat (FHD-286)
    3d
    Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) (clinicaltrials.gov)
    P2, N=244, Not yet recruiting, National Cancer Institute (NCI) | Initiation date: Dec 2025 --> Mar 2026
    Trial initiation date
    |
    Venclexta (venetoclax) • melphalan • fludarabine IV • busulfan
    3d
    Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy) (clinicaltrials.gov)
    P2, N=132, Not yet recruiting, National Cancer Institute (NCI) | Initiation date: Feb 2026 --> May 2026
    Trial initiation date
    |
    Venclexta (venetoclax) • Inqovi (decitabine/cedazuridine) • Rezlidhia (olutasidenib)
    3d
    Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, University of Alabama at Birmingham | Initiation date: Oct 2025 --> Feb 2026
    Trial initiation date
    |
    Venclexta (venetoclax) • decitabine • melphalan
    3d
    Pharmacological Inhibition of miR-126 Enhances Venetoclax Activity in Acute Myeloid Leukemia. (PubMed, Blood)
    Leukemic stem cells (LSCs) in acute myeloid leukemia (AML) depend on oxidative phosphorylation (OXPHOS) sustained by fatty acid oxidation (FAO) and mitochondrial fusion (mitofusion). In vivo, miRisten potentiated the VEN/azacitidine (AZA) regimen, an FDA-approved therapy for older or unfit AML patients, significantly prolonging survival in patient-derived xenograft models. VEN/miRisten combination also reduced LSC burden and restored VEN sensitivity, establishing miR-126 inhibition as a transformative therapeutic strategy in AML.
    Journal
    |
    BCL2 (B-cell CLL/lymphoma 2) • MIR126 (MicroRNA 126)
    |
    Venclexta (venetoclax) • azacitidine
    3d
    UHRF1 Overexpression Generates Distinct Senescent States with Different Tp53 Dependencies. (PubMed, bioRxiv)
    The senolytic Navitoclax targeted only a subset of senescent cells. Thus, the diversity of senescent cells driven by epigenetic changes can generate divergent outcomes. UHRF1 overexpression in zebrafish hepatocytes induces DNA damage leading to Atm-tp53-dependent senescence with UHRF1 levels dictating whether hepatocytes remain senescent, escape, or undergo senolytic elimination.
    Journal
    |
    TP53 (Tumor protein P53) • UHRF1 (Ubiquitin Like With PHD And Ring Finger Domains 1)
    |
    navitoclax (ABT 263)
    5d
    EUREKA-VEN: Study of the Relationship Between the Pharmacokinetics (PK) and Pharmacodynamics of Venetoclax in Patients With Acute Myeloblastic Leukemia (clinicaltrials.gov)
    P=N/A, N=100, Recruiting, Centre Leon Berard | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Venclexta (venetoclax)